Kronos Bio【KRON】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.00

買値

0.95

売値

1.00

出来高

100

0.00 日の範囲 0.00

0.69 52 週間の範囲 1.60

時価総額

60.341M

前日終値

1.00

始値

時刻

100

(formt)

最終取引時間

20:54:07

財務取引量

VWAP

平均取引量 (3 か月)

298,228

発行済株式数

60,340,918

配当利回り

PER

-0.54

1 株当たり利益 (EPS)

-1.87

歳入

6.29M

純利益

-112.67M

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.kronosbio.com

本社

Wilmington, Delaware, USA

設立

Kronos Bio Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker KRON. The last closing price for Kronos Bio was US$1. Over the last year, Kronos Bio shares have traded in a share price range of US$ 0.69 to US$ 1.60.

Kronos Bio currently has 60,340,918 shares in issue. The market capitalisation of Kronos Bio is US$60.34 million. Kronos Bio has a price to earnings ratio (PE ratio) of -0.54.

Kronos Bio Announces CEO Transition and Reduction in Force

– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and...

Form EFFECT - Notice of Effectiveness

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo...

Form 8-K - Current report

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

– Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio...

Form S-3 - Registration statement under Securities Act of 1933

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place...

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.01	1.0101010101	0.99	1.03	0.9504	191919	0.9986338	CS
4	0.05	5.26315789474	0.95	1.03	0.8902	331737	0.95443231	CS
12	0.0514	5.41851149062	0.9486	1.09	0.8	298228	0.94196785	CS
26	-0.26	-20.6349206349	1.26	1.46	0.8	177990	0.96614327	CS
52	-0.09	-8.25688073394	1.09	1.6	0.69	287967	1.03894873	CS
156	-8.53	-89.5068205666	9.53	10.94	0.69	295260	2.42798746	CS
260	-27.29	-96.4651820431	28.29	39.605	0.69	280266	8.10928167	CS

KRON - Frequently Asked Questions (FAQ)

What is the current Kronos Bio share price?

The current share price of Kronos Bio is US$ 1.00

How many Kronos Bio shares are in issue?

Kronos Bio has 60,340,918 shares in issue

What is the market cap of Kronos Bio?

The market capitalisation of Kronos Bio is USD 60.34M

What is the 1 year trading range for Kronos Bio share price?

Kronos Bio has traded in the range of US$ 0.69 to US$ 1.60 during the past year

What is the PE ratio of Kronos Bio?

The price to earnings ratio of Kronos Bio is -0.54

What is the cash to sales ratio of Kronos Bio?

The cash to sales ratio of Kronos Bio is 9.6

What is the reporting currency for Kronos Bio?

Kronos Bio reports financial results in USD

What is the latest annual turnover for Kronos Bio?

The latest annual turnover of Kronos Bio is USD 6.29M

What is the latest annual profit for Kronos Bio?

The latest annual profit of Kronos Bio is USD -112.67M

What is the registered address of Kronos Bio?

The registered address for Kronos Bio is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Kronos Bio website address?

The website address for Kronos Bio is www.kronosbio.com

Which industry sector does Kronos Bio operate in?

Kronos Bio operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
DGNXDiginex Ltd	15.23 (103.07%)	696.64k
FSEAFirst Seacoast Bancorp Inc	US$ 15.90 (59.00%)	7
BKHABlack Hawk Acquisition Corporation	US$ 16.55 (58.98%)	9
BBGIBeasley Broadcast Group Inc	US$ 13.31 (58.45%)	14
CRWSCrown Crafts Inc	US$ 6.99 (56.03%)	1
VIRCVirco Manufacturing Company	US$ 6.01 (-45.86%)	70
CPBICentral Plains Bancshares Inc	US$ 10.01 (-31.67%)	8
TSBKTimberland Bancorp Inc	US$ 21.01 (-27.63%)	15
XNCRXencor Inc	US$ 15.01 (-27.38%)	16
UBFOUnited Security Bancshares	US$ 7.21 (-27.25%)	15
QNRXQuoin Pharmaceuticals Ltd	US$ 0.8071 (36.89%)	21.86M
KOPNKopin Corporation	US$ 1.89 (28.57%)	17.79M
HEPAHepion Pharmaceuticals Inc	US$ 0.162 (20.00%)	12M
ASSTAsset Entities Inc	US$ 1.44 (5.88%)	7.02M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.3229 (1.22%)	6.9M